CO2022000700A2 - Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos - Google Patents

Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Info

Publication number
CO2022000700A2
CO2022000700A2 CONC2022/0000700A CO2022000700A CO2022000700A2 CO 2022000700 A2 CO2022000700 A2 CO 2022000700A2 CO 2022000700 A CO2022000700 A CO 2022000700A CO 2022000700 A2 CO2022000700 A2 CO 2022000700A2
Authority
CO
Colombia
Prior art keywords
pyridazin
diamino
derivatives
pharmaceutical compositions
compositions containing
Prior art date
Application number
CONC2022/0000700A
Other languages
English (en)
Inventor
Jérôme-Benoît Starck
Maïa Chanrion
James Edward Paul Davidson
James Brooke Murray
Ana Leticia Maragno
Miklós Nyerges
Frédéric Colland
Patrice Desos
Tibor Novak
Attila Paczal
András Kotschy
Simon Bedford
Mark Philip Dodsworth
András Herner
Mátyás Pál Timári
Paul Webb
Petra Dunkel
Márk Molnár
Rachel Jane Parsons
Monika Rudasová
Zoltán Madarász
Marianna Szigeti
Ágnes Strofek
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CO2022000700A2 publication Critical patent/CO2022000700A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos de fórmula (I) en donde Het1, Het2, R1, R2 y R3 son como se definen en la descripción. Medicamentos.
CONC2022/0000700A 2019-07-29 2022-01-26 Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos CO2022000700A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (1)

Publication Number Publication Date
CO2022000700A2 true CO2022000700A2 (es) 2022-02-07

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000700A CO2022000700A2 (es) 2019-07-29 2022-01-26 Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Country Status (20)

Country Link
US (1) US20220289734A1 (es)
EP (1) EP4003988A1 (es)
JP (1) JP2022542937A (es)
KR (1) KR20220042182A (es)
CN (1) CN114450283B (es)
AR (1) AR119493A1 (es)
AU (1) AU2020322072A1 (es)
BR (1) BR112022001330A2 (es)
CA (1) CA3148502A1 (es)
CL (1) CL2021003594A1 (es)
CO (1) CO2022000700A2 (es)
CR (1) CR20220014A (es)
GE (1) GEP20247670B (es)
IL (1) IL289932A (es)
JO (1) JOP20220006A1 (es)
MX (1) MX2022001161A (es)
PE (1) PE20220704A1 (es)
TW (1) TW202118761A (es)
UY (1) UY38809A (es)
WO (1) WO2021018857A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198996A1 (en) * 2020-11-24 2022-06-02 Matthew T. Burger Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN117794929A (zh) * 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
AR129382A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
MX2010006457A (es) * 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11201709837RA (en) * 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Also Published As

Publication number Publication date
TW202118761A (zh) 2021-05-16
GEP20247670B (en) 2024-09-25
KR20220042182A (ko) 2022-04-04
IL289932A (en) 2022-03-01
AU2020322072A1 (en) 2022-02-10
CN114450283A (zh) 2022-05-06
CN114450283B (zh) 2024-05-07
EP4003988A1 (en) 2022-06-01
BR112022001330A2 (pt) 2022-05-17
WO2021018857A1 (en) 2021-02-04
PE20220704A1 (es) 2022-05-04
MX2022001161A (es) 2022-02-22
JP2022542937A (ja) 2022-10-07
AR119493A1 (es) 2021-12-22
CA3148502A1 (en) 2021-02-04
CL2021003594A1 (es) 2022-11-18
UY38809A (es) 2021-02-26
US20220289734A1 (en) 2022-09-15
JOP20220006A1 (ar) 2023-01-30
CR20220014A (es) 2022-03-02

Similar Documents

Publication Publication Date Title
CO2022000612A2 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
CO2022000700A2 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2018001908A1 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ES2039269T3 (es) Derivados de azolilmetil-ciclopropilo.
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2019003281A1 (es) Derivados de piperidina. (divisional solicitud 201900169)
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY30493A1 (es) Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones
UY32286A (es) Nuevos derivados de pirrolidindiona espiroheterocíclica n-oxiamida
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2020001817A1 (es) Moduladores del receptor c5a
CO2021004553A2 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen